GlobalData on MSN3d
MaxCyte and Kamau Therapeutics sign platform license agreementKamau Therapeutics will gain non-exclusive research, clinical and commercial rights to utilise MaxCyte's Flow Electroporation ...
BTQ Technologies Corp. (the "Company") (CBOE CA: BTQ) (FSE: NG3) (OTCQX: BTQQF), a global quantum technology company focused ...
IFLScience on MSN4d
Asgard Archaea: Are These Single-Celled Organisms Our Microbial Ancestors?It’s undeniable at this point that Asgard archaea contributed a lot to the complexity that we see in eukaryotes today.” ...
Under the terms of the agreement, Kamau obtains non-exclusive research, clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERTTM platform. In return, MaxCyte is ...
The discovery of Shishania aculeata, a shell-less early Cambrian mollusk, sheds light on the evolutionary development of ...
MaxCyte, Inc., (MXCT, MXCT.L), a cell-engineering focused company, Monday announced that it has entered into a strategic platform ...
Cell engineering technology company MaxCyte announced a strategic platform licence agreement with Kamau Therapeutics, a ...
The company's platform, which is founded on homology-directed repair (HDR) editing, builds on first generation CRISPR-Cas9 technology by not only cutting DNA but providing a template to repair DNA.
The nuclease Cas9 and DNA-repair pathway homology-mediated end joining can be leveraged to efficiently and non-virally integrate large DNA payloads into genomic target sites in primary T cells.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback